**CASE REPORT**

Haemoglobin Marseille-Long Island and interpretation of HbA1c: which HbA1c result is the “right answer”?  

C M Florkowski, T A Walmsley, S O Brennan, P M George

A woman was screened for diabetes using glycated haemoglobin (HbA1c). Vastly different results were obtained by high performance liquid chromatography (4.5%), immunoassay (2.9%), and affinity chromatography (4.2%) compared with the non-diabetic range of less than 6.4%. Mass spectral studies confirmed the presence a haemoglobin variant, haemoglobin Marseille-Long Island which had confounded interpretation by all methods.

---

**DISCUSSION**

The initial HbA1c of 45% by HPLC is implausibly high, especially in an asymptomatic woman with a low probability of diabetes. This raised suspicion of a possible haemoglobin variant. Haemoglobin electrophoresis on cellulose acetate (pH 8.6) gave a normal pattern. This prompted the decision to undertake mass spectrometry studies of HbA1c.

Mass spectrometry excluded a HbA1c of 45% and confirmed that the subject was heterozygous for haemoglobin Marseille-Long Island. This variant, originally termed haemoglobin Marseille was originally described in a diabetic Maltese woman, and subsequently termed haemoglobin Long Island. Structural analysis revealed the presence of a methionyl residue extending the amino terminus of the β chain and a histidine to proline substitution at the second position in the β chain. This substitution of a positively charged amino acid with a neutral one results in a net loss of one positive charge. Haemoglobin Marseille-Long Island therefore has an amino terminal that is modified in a way that does not permit recognition by the antibodies of the DCA 2000 assay. Given that the subject is heterozygous for this variant and that half the β chains are therefore normal, then arguably the “correct” answer might be obtained by doubling the DCA 2000 result. This would give a value of 5.8%, which is plausible.

Affinity chromatography relies on a fundamentally different analytical principle, namely a covalent interaction between cis-diol groups in the glycated haemoglobin molecule (at all sites and not just the amino terminus of the β chain) and boronate residues in the affinity resin. Results are usually adjusted to give HbA1c equivalents and this method is the one normally considered to be least affected by haemoglobin variants. The modification of the amino terminus of the β globin chain in haemoglobin Marseille-Long Island, in particular the methionyl extension means that the fraction that is technically HbA1c does not exist. The absence of glycation at this site results in a value that is artefactually low. In the absence of any other evidence, this result, which is biologically plausible might have been accepted as “correct” in the present case.

---

**Abbreviations:** HbA1c, glycated haemoglobin; HPLC, high performance liquid chromatography.

---

**Figure 1** Mass spectral analysis of control and patient lysate showing variant β chain (β.mar) with a mass increase of 91 Da. This histidine to proline substitution decreases the mass by 40 Da and the addition of N terminal methionine results in a mass increase of 131.
Learning points

- Haemoglobin variants can interfere with most HbA1c methods and cause problems with interpretation.
- The possibility of haemoglobin variants should be considered when HbA1c results do not concur with clinical expectations.
- Haemoglobin variants may not always be revealed by electrophoresis.
- Analysis of HbA1c by alternative methods, in particular by mass spectrometry, may help to elucidate the nature of confounding variants.
- It is occasionally necessary to consider alternative measures of glycation than HbA1c.

None of the obtained results therefore gives the “right answer” for glycaemic status. As indicated above, doubling of the DCA 2000 result may be argued as giving the “right answer” for glycaemic status. As indicated above, doubling of the DCA 2000 result may be argued as giving the “right answer” for glycaemic status.

Notwithstanding all of the above considerations, the predictive value of HbA1c for diabetes depends on the chosen cut off and is not usually recommended as a screening test.”

------------------------------------

AUTHORS’ AFFILIATIONS

C M Florkowski, T A Walmsley, S O Brennan, P M George, Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand

Correspondence to: Dr Florkowski; chris.florkowski@cdhb.govt.nz

Submitted 13 November 2002
Accepted 19 December 2002

REFERENCES


------------------------------------

CALL FOR FILLERS

The Postgraduate Medical Journal invites readers to contribute fillers for the journal. They can be on any topic likely to be of interest but we particularly welcome fillers on the following:

- Self help groups.
- Favourite books.
- Life defining moments or patients.
- Medical history.

Fillers, of around 250 words, can be emailed to the editor at pmj@btinternet.com for consideration.